T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Apple
AAPL
|
+$4.53B |
| 2 |
Broadcom
AVGO
|
+$1.7B |
| 3 |
GE Vernova
GEV
|
+$1.29B |
| 4 |
International Paper
IP
|
+$1.11B |
| 5 |
Tesla
TSLA
|
+$956M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$2.44B |
| 2 |
NVIDIA
NVDA
|
+$2.09B |
| 3 |
Constellation Energy
CEG
|
+$1.9B |
| 4 |
Qualcomm
QCOM
|
+$1.84B |
| 5 |
Amazon
AMZN
|
+$1.56B |
Sector Composition
| 1 | Technology | 34% |
| 2 | Healthcare | 14.89% |
| 3 | Financials | 10.35% |
| 4 | Consumer Discretionary | 10.1% |
| 5 | Communication Services | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LL
2676
DELISTED
LL Flooring Holdings, Inc.
LL
| $140K | ﹤0.01% |
97,400
| – | – |
|
2677
Stereotaxis
STXS
$256M
| $139K | ﹤0.01% |
76,199
+17,799
| +30% | +$32.5K |
|
2678
Arbutus Biopharma
ABUS
$886M
| $138K | ﹤0.01% |
44,526
+8,138
| +22% | +$25.2K |
|
|
KG
2679
Kestrel Group, Ltd.
KG
$199M
| $138K | ﹤0.01% |
3,346
+23
| +0.7% | +$949 |
|
|
TPIC
2680
DELISTED
TPI Composites
TPIC
| $138K | ﹤0.01% |
34,347
| – | – |
|
2681
Veritone
VERI
$201M
| $137K | ﹤0.01% |
60,500
-8,028
| -12% | -$18.2K |
|
2682
Altice USA
ATUS
$1.09B
| $136K | ﹤0.01% |
66,400
+15,700
| +31% | +$32.2K |
|
2683
Astria Therapeutics
ATXS
$423M
| $136K | ﹤0.01% |
14,884
+681
| +5% | +$6.22K |
|
2684
Frontier Group Holdings
ULCC
$1.17B
| $136K | ﹤0.01% |
27,491
+1,481
| +6% | +$7.33K |
|
2685
iHeartMedia
IHRT
$323M
| $135K | ﹤0.01% |
123,339
| – | – |
|
2686
Humacyte
HUMA
$234M
| $135K | ﹤0.01% |
28,069
+12,216
| +77% | +$58.8K |
|
2687
GCM Grosvenor
GCMG
$681M
| $134K | ﹤0.01% |
13,679
+1,218
| +10% | +$11.9K |
|
2688
ARS Pharmaceuticals
SPRY
$1.04B
| $134K | ﹤0.01% |
+15,720
| New | +$134K |
|
|
DM
2689
DELISTED
Desktop Metal, Inc.
DM
| $134K | ﹤0.01% |
32,230
-7,498
| -19% | -$31.2K |
|
2690
LifeVantage
LFVN
$143M
| $133K | ﹤0.01% |
20,700
| – | – |
|
2691
Heron Therapeutics
HRTX
$195M
| $132K | ﹤0.01% |
37,495
+7,573
| +25% | +$26.7K |
|
|
ENFN
2692
DELISTED
Enfusion, Inc.
ENFN
| $132K | ﹤0.01% |
15,457
+4,444
| +40% | +$38K |
|
2693
Inseego
INSG
$199M
| $131K | ﹤0.01% |
12,270
| – | – |
|
2694
MaxCyte
MXCT
$151M
| $131K | ﹤0.01% |
33,405
+8,206
| +33% | +$32.2K |
|
2695
Tango Therapeutics
TNGX
$708M
| $131K | ﹤0.01% |
15,234
+2,463
| +19% | +$21.2K |
|
2696
Akebia Therapeutics
AKBA
$777M
| $130K | ﹤0.01% |
126,648
+66,748
| +111% | +$68.5K |
|
2697
Great Lakes Dredge & Dock
GLDD
$815M
| $130K | ﹤0.01% |
14,802
| – | – |
|
2698
Fossil Group
FOSL
$159M
| $129K | ﹤0.01% |
88,900
-10,588
| -11% | -$15.4K |
|
2699
Atomera
ATOM
$101M
| $128K | ﹤0.01% |
33,500
+4,967
| +17% | +$19K |
|
2700
Nano X Imaging
NNOX
$242M
| $128K | ﹤0.01% |
17,332
+3,616
| +26% | +$26.7K |
|